Financial Report

Overview

The report describes Acrux's expansion of its generic topical pharmaceutical portfolio, including 15 ANDA products and three FDA approvals. Group revenue from continuing operations increased to $5.156 million. A $17.747 million capital raise supported pipeline development, commercialisation activity and working capital.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2021
Period: Ends 30 June 2021
Publication date: 25 August 2021
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services